Pink Sheet Podcast: The Most Impactful Stories Of 2019
Executive SummaryPink Sheet reporters review the major issues that emerged during the past year and how they will impact 2020.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.
US Energy and Commerce Committee leaders request data on complex generic approvals, guidances, saying additional changes may be needed for faster approvals.